nCCR for Chemotherapy Related Cognitive Impairment Randomized Study

Chemo-brain Clinical Trial

Official title: Neuroplasticity-Based Cognitive Remediation for Chemotherapy Related Cognitive Impairment Randomized Study

Status Recruiting

Clinical Trial Summary

The investigators propose to apply neuroplasticity-based computerized cognitive remediation (nCCR) to treat chemotherapy-related cognitive impairment (CRCI).

Clinical Trial Description

Successes in breast cancer treatment are resulting in a growing number of cancer survivors. This has broadened the scope of care from treating the disease alone to improving the quality of life of cancer survivors. Chemotherapy-related cognitive impairment (CRCI), often referred to by patients as 'chemobrain,' is a common and highly distressful side effect of chemotherapy often reported by breast cancer survivors. Managing the symptoms of CRCI should be integrated with routine cancer care as these symptoms diminish quality of life, impair work performance, and make it more difficult for patients to follow treatment regimens. CRCI can persist for months to years following cancer treatment. However, there are currently no established treatments for CRCI.

The most commonly reported CRCI symptoms in breast cancer survivors include problems with executive functions. Executive function is a cognitive domain involved in planning, problem-solving, organization, and time management. In order to improve executive dysfunction and quality of life in breast cancer survivors, we propose to use a new brain training program called neuroplasticity-based computerized cognitive remediation (nCCR). The term 'neuroplasticity' refers to the brain's ability to modify, change, and adapt throughout life and in response to experience. Neuroplacticity can be induced through the use of focused brain training that nCCR offers. Past work demonstrates that this neuroscience-guided brain training benefits other patient populations with similar cognitive problems and has shown preliminary success in cancer survivors in a small pilot study. If successful, this treatment could have significant benefits for large numbers of breast cancer survivors. ;

Related Conditions & MeSH terms

• Chemo-brain
• Chemotherapy-Related Cognitive Impairment
• Cognitive Dysfunction

• NCT number: NCT05283629
• Study type: Interventional
• Source: Vanderbilt University Medical Center
• Contact: Nicole T Nguyen, MA
• Phone: (615) 327-7030
• Email: nicole.tp.nguyen@vumc.org
• Status: Recruiting
• Phase: N/A
• Start date: August 1, 2022
• Completion date: March 1, 2025